GalNac Peptide Conjugate
* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
Online Inquiry
What is GalNac Peptide Conjugate?
The GalNAc peptide conjugate molecule is one of the most fascinating types of therapeutic entities in the domain of pharmacology. It consists of a peptide or protein drug that is intricately connected to a GalNAc (N-acetylgalactosamine) molecule, forming a remarkable hybrid structure. This complex architecture aims to enhance the selectivity and transport of the therapeutic agent to desired cellular and tissue sites while simultaneously mitigating the danger of non-specific, off-target effects.
Structure of GalNac Peptide Conjugate
The intriguing world of GalNac peptide conjugates is populated by a diverse and complex array of molecular entities, each comprising of two key building blocks. The first component is the GalNAc moiety, an exquisitely-tailored N-acetylgalactosamine sugar molecule that is seamlessly integrated with the second core constituent, a peptide moiety. The two entities are deftly linked via a linker entity that enables the GalNAc peptide conjugate to achieve a state of perfect balance and structural integrity.
Advantages of GalNac Peptide Conjugation for targeted drug delivery
High Specificity: The high specificity of GalNAc, stoked by its predilection towards the asialoglycoprotein receptor (ASGPR), which is dominantly expressed on the surface of liver cells, is a marvel of precision medicine.
Increased Drug Bioavailability: The efficacy of GalNAc peptide conjugates in drug delivery stems from their ability to elevate the bioavailability of drugs by specifically targeting the liver, with no loose ends or heedless slip-ups. This exquisite targeting of the liver by GalNAc peptide conjugates has the potential to significantly reduce the dosing frequency, thereby making the therapy more efficacious and cost-effective.
Reduced Systemic Toxicity: GalNAc peptide conjugates may also reduce the risk of systemic toxicity that may arise with conventional drug delivery methods. This is possible because the conjugates, purposefully targeting the liver, dodge the scourge of nonspecificity.
Which diseases can be studied by GalNac Peptide Conjugate?
Genetic disorders: Such as hemophilia and cystic fibrosis. In these diseases, the GalNAc peptide conjugate can correct the underlying genetic mutation, leading to a functional protein that can alleviate disease symptoms.
Viral infections: Such as hepatitis B and C. The GalNAc peptide conjugate can inhibit viral replication by targeting essential viral proteins, preventing the virus from replicating and spreading.
Cancer: The GalNAc peptide conjugate can induce apoptosis in cancer cells, leading to their death and preventing the spread of the disease.
Our Services
- Glycosylation of peptides
- Galnac peptide conjugate
- Glycosylated amino acids
- Modification of peptide with different sugar entities
